Oral phosphate binders for the management of serum phosphate levels in dialysis patients

Journal of Renal Care

Volumn 35, Issue SUPPL. 1, 2009, Pages 65-70

  Mohammed, Ismail ^a   Hutchison, Alastair J ^b  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Chronic kidney disease; Dialysis; Guidlines; Pharmaceuticals; Phosphate

Indexed keywords

ACETIC ACID DERIVATIVE; ALUMINUM HYDROXIDE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM DERIVATIVE; CHELATING AGENT; LANTHANUM; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CARBONATE; PHOSPHORUS; POLYAMINE; SEVELAMER;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DRUG MONITORING; HUMAN; HYPERPHOSPHATEMIA; METHODOLOGY; MORTALITY; NEPHROLOGY; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

ACETATES; ADMINISTRATION, ORAL; ALUMINUM HYDROXIDE; CALCIUM CARBONATE; CALCIUM COMPOUNDS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DRUG MONITORING; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MAGNESIUM; NEPHROLOGY; PATIENT EDUCATION AS TOPIC; PHOSPHORUS; POLYAMINES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 61649091571     PISSN: 17556678     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2009.00052.x     Document Type: Article

References (42)

1. Al-Baaj F., Speake M. & Hutchison A.J. (2005). Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebocontrolled study. Nephrology, Dialysis, Transplantation 20, 775-782.
2. Bleyer A.J., Burke S.K., Dilton M. et al. (1999). A comparison of a calcium free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphataemia in haemodialysis patients. American Journal of Kidney Disease 33, 694-701.
3. Block G.A., Klassen P.S., Lazarus J.M. et al. (2004). Mineral metabolism, mortality and morbidity in maintenance haemodialysis. Journal of American Society of Nephrology 15, 2208-2218.
4. Block G.A. & Port F.K. (2000). Re-evaluation of risks associated with hyperphosphataemia and hyperparathyroidism in dialysis patients: recommendation for change in management. American Journal of Kidney Disease 35, 1226-1237.
5. Chertow G.M., Burke S.K., Raggi R Treat to Goal Working Group. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International 62, 245-252.
6. Damment S.J. & Pennick M. (2007). Systemic lanthanum is excreted in the bile of rats. Toxicology Letters 171, 69-77.
7. Delmez J. & Slatopolsky E. (1992). Hyperphosphatemia, its consequence and treatment in patients with chronic renal failure. American Journal of Kidney Disease 4, 313-317.
8. Delmez J.A., Slatopolsky E., Martin K.J. et al. (1982). Mineral, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney International 21, 862-867.
9. D'Haese P.C., Spasovski G.B., Sikole A. et al. (2003). A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International. Supplement 85, S73-S78.
10. Finn W.F., Joy M.S. & Haldick G.A. (2004). Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clinical Nephrology 62, 193-201.
11. Finn W.F., SPD 405-307 Lanthanum Study Group. (2006). Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clinical Nephrology 65, 191-202.
12. Ford J.C., Pope J.F., Hunt A.E. & Gerald 8. (2004). The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphataemia. Journal of Renal Nutrition 14, 36-44.
13. Gonzalez-Revalderia J., Casares M., de Paula M. et al. (2000). Biochemical and haematological changes in low-level aluminium intoxication. Clinical Chemistry and Laboratoiy Medicine 38, 221-225.
14. Goodman W.G. (2001). Vascular calcifi cation in chronic renal failure. Lancet 358, 1115-1116.
15. Goodman W.G., Goldin J., Kuizon B.D. et al. (2000). Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New England Journal of Medicine 342, 1478-1483.
16. Hutchison A.J., Merchant M., Boulton H.F. et al. (1993). Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid. Peritoneal Dialysis International 13(3), 219-223.
17. Hutchison A.J., Were A.J., Boulton H.F. et al. (1996). Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. Nephron 72(1), 52-58.
18. Hutchison A.J., Barnett M.E., Krause R. et al. on behalf of the SPD405-309 Lanthanum Study Group. (2008). Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron. Clinical Practice. 110(1), c15-c23[Epub].
19. Hutchison A.J., Laville M. on behalf of the SPD405-313 Lanthanum Study Group. (2008). Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrology, Dialysis, Transplantation, 23(11), 3677-3684.
20. Hutchison A.J., Maes B., Vanwalleghern J. et al. (2005). Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron. Clinical Practice 100, cs-c19.
21. Knoll O., Kellinghaus H., Betram H.P. et al. (1984). Gastrointestinal absorption of aluminium in chronic renal insufficiency. Contributions to Nephrology 38, 24-31.
22. Kopple J.D. & Coburn J.W. (1973). Metabolic studies of low protein diet in uraemia: 11.Calcium, phosphorous, and magnesium. Medicine 52, 597-607.
23. Kuhlmann M.K., Hoechst S. & Landthaler I. (2007). Patient empowerment in the management of hyperphosphatemia. International Journal of Artificial Organs 30, 1008-1013
24. Lamb E.J., Hodsman A., van Schalkwyk D. et al. (2007). Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (Chapter 9). Nephrology, Dialysis, Transplantation 22(Suppl 7), 105-118.
25. Lowrie E.G. & Lew N.L. (1990). Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Disease 15, 458-482.
26. Macia M., Comel F., Navarro J.F. et al. (1997). Calcium salts of keto-amino acids; A phosphate binder alternative for patients on CAPD. Clinical Nephrology 48(3), 181-184.
27. Mai M., Emmett M., Sheikh M. et al. (1989). Calcium acetate an effective phosphate binder in patients with renal failure. Kidney International 36, 690-695.
28. Malluche H.H. (2002). Aluminium and bone disease in chronic renal failure. Nephrology, Dialysis, Transplantation 17(Suppl 2), 21-24.
29. McIntyre C.W. (2007). New developments in the management of hyperphosphatemia in chronic kidney disease. Seminars in Dialysis 20, 337-341.
30. Meema H.E., Oreopoulos D.G. & Rapoport A. (1987). Serum magnesium level and arterial calcification in end-stage renal disease. Kidney International 32(3), 388-394.
31. Nilsson P., Johansson S.G. & Danielson B.G. (1984). Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium. Nephron 37, 25-29
32. O'Donovan R., Baldwin D., Hammer M. et al. (1986). Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet I, 880-881.
33. Pennick M., Dennis K. & Damment S.J. (2006). Absolute bioavailability and disposition of lanthanurn in healthy human subjects administered lanthanum carbonate. Journal of Clinical Pharmacology 46, 738-746.
34. Qunibi W.Y., Hootkins R.E., McDowell L.L. et al. (2004). Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney International 65, 1914-1926.
35. Schaefer K., Umlauf E. & von Herrath D. (1992). Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. American Journal of Kidney Disease 19, 460-464.
36. Slatopolsky E., Weerts C., Lopez-Hilker S. et al. (1986). Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. New England Journal of Medicine 315, 157-161
37. Spiegel D.M. (2007). The role of magnesium binders in chronic kidney disease. Seminars in Dialysis 20(4), 333-336.
38. Spiegel D.M., Farmer B., Smits G. et al. (2007). Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition 17(6), 416-422.
39. Suki W.N., Zabaneh R., Cangiano J.L. et al. (2007). Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International 72, 1130-1137
40. Sun C.Y., Chang K.C., Chen S.H. et al. (2008). Patient education: an efficient adjuvant therapy for hyperphosphataemia in demodialysis patients. Renal Failure 30, 57-62
41. Turgut F., Kanbay M., Metin M.R. et al. (2008). Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. International Urology and Nephrology Jun 21. [Epub ahead of print].
42. Wills M.R. & Savory J. (1983). Aluminium poisoning: dialysis encephalopathy, osteomalacia and anaemia. Lancet 2, 29-34.